The technology involves the development of two specific anti-idiotype monoclonal antibodies, N6-I and N6-2, which target a broadly neutralizing monoclonal antibody (mAb), N6, known for its effectiveness against HIV. These anti-idiotype antibodies are crucial for detecting and monitoring the N6 mAb's quality and quantity in various settings, including in vivo, in vitro, and in clinical trials.

These antibodies are essential tools for researchers and clinicians working on HIV prevention and treatment strategies. They enable the accurate measurement and tracking of the N6 mAb, which is vital for assessing its efficacy and optimizing its use in therapeutic and preventive interventions. The development of these anti-idiotype antibodies represents a significant advancement in HIV research and could lead to improved strategies for combating the virus.